TABLE 2.

Immunophenotypic characterization of UET-13 transfectants and EFT cells

MPC statusaCD markerResult forb:EFT statuscSK-ES1
UET-13UET-13TRUET-13TR- EWS/FLI1UET-13TR- EWS/ERGRD-ES
TetTet+TetTet+TetTet+
M+CD29+++++++++
M+CD59+++++++++
M+CD90+++++++++E+
M+CD105+++++++++
M+CD166+++++++++
M+CD44+++++++
M+CD73+++++++
M+CD10++++Down+Down
M+CD13++++Down+Down
M+CD49e++++Down+Down+
M+CD61++++Down+Down
M+CD55++++Down+++
M+CD54UpUp++E+
M(−)CD117UpUp++E+
M+/−CD271UpUp++E+
CD40++E+
CD56++E+
M(−)CD133++
M(−)CD14
M(−)CD34
M(−)CD45
  • a M(−), negative for MPCs; M+/−, positive for BM-derived MPCs but negative after in vitro culture; M+, positive for MPCs.

  • b +, most cells positive; −, negative; Up, up-regulated by tetracycline treatment; Down, down-regulated by tetracycline treatment. Boldface indicates the antigens the immunophenotypes of which were changed in favor of EFT. Tet, tetracycline negative; Tet+, tetracycline positive.

  • c E+, positive for EFTs.